ALERT: Why Cannabis Stocks Can Celebrate Today!

While questions surround the Presidential election, cannabis stocks like Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) have reason to celebrate.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The United States Presidential Election took place yesterday and big turnout reflected the intensity of the contest in 2020. At the time of this writing, top battleground states like Michigan, Pennsylvania, Wisconsin, and Georgia were still tallying votes. Earlier this week, I’d discussed why the presidential race held little promise for cannabis stocks.

At best, Biden and Trump have been ambivalent on the cannabis question. However, I’d also discussed legalization votes that were set to take place in several states. On this front, there is cause for celebration.

Recreational cannabis legalized in New Jersey, Arizona, and Montana.

Big results in the United States could propel cannabis stocks

While votes for the presidential race are still being counted, we have some big news on votes for cannabis legalization. Arizona, New Jersey, and Montana have all voted to legalize recreational cannabis use, according to current vote projections. South Dakota will be the first state ever to approve medical and recreational cannabis measures at the same time. As we know in Canada, the vote is just the beginning. It will take time for recreational legalization to take shape.

Regardless, it is a very good result for an industry that’s sweeping across the United States. Canadians should watch cannabis stocks closely for the rest of this week. Indeed, could this result and improved sentiment south of the border give cannabis stocks a much-needed second wind?

Could cannabis get a second wind in the months ahead?

Canopy Growth (TSX:WEED)(NYSE:CGC) was one of the stocks I was bearish on ahead of the presidential election. Canada’s recreational legalization rollout has been imperfect, to put it nicely. Top producers like Canopy Growth are reliant on international expansion as domestic results have been sluggish.

Shares of Canopy Growth have climbed 43% month-over-month as of close on November 3. In October, Canopy announced a new distribution partnership with two major alcohol distributors; Reyes Beer Division and Manhattan Beer. Canopy aims to leverage these partnerships to bring its sports hydration brand, BioSteel, to U.S. consumers. This could pave the way for CBD and cannabis-infused beverages in the U.S. going forward.

Aurora Cannabis (TSX:ACB)(NYSE:ACB) is another top Canadian cannabis producer. This cannabis stock has plunged 80% so far this year. However, its shares have increased 22% week over week. Still, Aurora will need to build much more momentum to make up for its struggles over the past 12 months.

Its inability to score partnerships with major distributors, like Canopy has, is one of the reasons it has lost investor confidence. Strategist Nelson Peltz was brought on to facilitate a deal in that arena. Unfortunately, such a deal never materialized. Peltz resigned from Aurora Cannabis in late September.

On the plus side, this cannabis stock does boast a very favourable price-to-book value of 0.4.

More good news may be on the way for cannabis stocks

After today’s votes, one in three Americans now live in a state where recreational cannabis is legal. The world’s largest cannabis market has steadily liberalized over the last decade. Cannabis stocks like Canopy Growth and Aurora Cannabis will be in a great position to benefit if this trend can continue over the course of this decade.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »